These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The DNA methylation landscape of hematological malignancies: an update. Blecua P; Martinez-Verbo L; Esteller M Mol Oncol; 2020 Aug; 14(8):1616-1639. PubMed ID: 32526054 [TBL] [Abstract][Full Text] [Related]
3. Epigenetics in the hematologic malignancies. Fong CY; Morison J; Dawson MA Haematologica; 2014 Dec; 99(12):1772-83. PubMed ID: 25472952 [TBL] [Abstract][Full Text] [Related]
4. Epigenetics of hematopoiesis and hematological malignancies. Hu D; Shilatifard A Genes Dev; 2016 Sep; 30(18):2021-2041. PubMed ID: 27798847 [TBL] [Abstract][Full Text] [Related]
5. Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis. Langstein J; Milsom MD; Lipka DB Semin Cancer Biol; 2018 Aug; 51():89-100. PubMed ID: 28964938 [TBL] [Abstract][Full Text] [Related]
6. [A primer for epigenetics of hematological malignancies]. Nakajima H Rinsho Ketsueki; 2016; 57(10):1835-1844. PubMed ID: 27725578 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Pastore F; Levine RL Haematologica; 2016 Mar; 101(3):269-78. PubMed ID: 26928248 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic alterations in hematopoietic malignancies. Chung YR; Schatoff E; Abdel-Wahab O Int J Hematol; 2012 Oct; 96(4):413-27. PubMed ID: 23015417 [TBL] [Abstract][Full Text] [Related]
9. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets. Herranz M; Esteller M Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic programming contributes to development of drug resistance in hematological malignancies. Wang QY; Zhong H Front Biosci (Landmark Ed); 2015 Jan; 20(4):728-42. PubMed ID: 25553475 [TBL] [Abstract][Full Text] [Related]
11. Epigenetics in Cancer: A Hematological Perspective. Stahl M; Kohrman N; Gore SD; Kim TK; Zeidan AM; Prebet T PLoS Genet; 2016 Oct; 12(10):e1006193. PubMed ID: 27723796 [TBL] [Abstract][Full Text] [Related]
12. Epigenetics in prostate cancer: biologic and clinical relevance. Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191 [TBL] [Abstract][Full Text] [Related]
13. CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies. Sun C; Duan P; Luan C Curr Drug Targets; 2017; 18(10):1142-1151. PubMed ID: 28031014 [TBL] [Abstract][Full Text] [Related]
14. The potential of DNA modifications as biomarkers and therapeutic targets in oncology. Jankowska AM; Millward CL; Caldwell CW Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702 [TBL] [Abstract][Full Text] [Related]
15. Investigation of epigenetics in kidney cell biology. Li LX; Agborbesong E; Zhang L; Li X Methods Cell Biol; 2019; 153():255-278. PubMed ID: 31395383 [TBL] [Abstract][Full Text] [Related]
16. Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies. Markouli M; Strepkos D; Piperi C Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362442 [TBL] [Abstract][Full Text] [Related]